UK Standards for Microbiology Investigations

Investigation of urine
Acknowledgments

UK Standards for Microbiology Investigations (SMIs) are developed under the auspices of Public Health England (PHE) working in partnership with the National Health Service (NHS), Public Health Wales and with the professional organisations whose logos are displayed below and listed on the website https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories. SMIs are developed, reviewed and revised by various working groups which are overseen by a steering committee (see https://www.gov.uk/government/groups/standards-for-microbiology-investigations-steering-committee).

The contributions of many individuals in clinical, specialist and reference laboratories who have provided information and comments during the development of this document are acknowledged. We are grateful to the medical editors for editing the medical content.

For further information please contact us at:

Standards Unit
Microbiology Services
Public Health England
61 Colindale Avenue
London NW9 5EQ
E-mail: standards@phe.gov.uk

Website: https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories

PHE Publications gateway number: 2015306

UK Standards for Microbiology Investigations are produced in association with:

Logos correct at time of publishing.
Amendment table

<table>
<thead>
<tr>
<th>Amendment no/date.</th>
<th>18/11.01.19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Issue no. discarded.</td>
<td>8.6</td>
</tr>
<tr>
<td>Insert issue no.</td>
<td>8.7</td>
</tr>
<tr>
<td><strong>Section(s) involved</strong></td>
<td>Amendment</td>
</tr>
<tr>
<td>Section 4.7.1 Antimicrobial susceptibility testing and reporting table</td>
<td>A comment was added for Tazobactam which should not be tested or reported for <em>Acinetobacter</em> spp.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Amendment no/date.</th>
<th>17/07.08.18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Issue no. discarded.</td>
<td>8.5</td>
</tr>
<tr>
<td>Insert issue no.</td>
<td>8.6</td>
</tr>
<tr>
<td><strong>Section(s) involved</strong></td>
<td>Amendment</td>
</tr>
<tr>
<td>Section 2.2 Optimal time and method of collection.</td>
<td>Removed recommendation for periurethral cleaning in mid-stream urine (MSU) collection.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Amendment no/date.</th>
<th>16/01.05.18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Issue no. discarded.</td>
<td>8.4</td>
</tr>
<tr>
<td>Insert issue no.</td>
<td>8.5</td>
</tr>
<tr>
<td><strong>Section(s) involved</strong></td>
<td>Amendment</td>
</tr>
<tr>
<td>Section 5.2 Culture.</td>
<td>Typo amended in text.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Amendment no/date.</th>
<th>15/16.08.17</th>
</tr>
</thead>
<tbody>
<tr>
<td>Issue no. discarded.</td>
<td>8.3</td>
</tr>
<tr>
<td>Insert issue no.</td>
<td>8.4</td>
</tr>
<tr>
<td><strong>Section(s) involved</strong></td>
<td>Amendment</td>
</tr>
</tbody>
</table>

Each SMI method has an individual record of amendments. The current amendments are listed on this page. The amendment history is available from standards@phe.gov.uk.

New or revised documents should be controlled within the laboratory in accordance with the local quality management system.
<table>
<thead>
<tr>
<th>Page 19 Interpretation of culture.</th>
<th>Bacteria levels have been corrected.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amendment no/date.</td>
<td>14/07.08.17</td>
</tr>
<tr>
<td>Issue no. discarded.</td>
<td>8.2</td>
</tr>
<tr>
<td>Insert issue no.</td>
<td>8.3</td>
</tr>
<tr>
<td><strong>Section(s) involved</strong></td>
<td>Amendment</td>
</tr>
<tr>
<td>Page 14 Organisms implicated</td>
<td>Spelling error corrected.</td>
</tr>
<tr>
<td>in UTI.</td>
<td></td>
</tr>
<tr>
<td>Page 14 Organisms implicated</td>
<td>Reorganisation of some text.</td>
</tr>
<tr>
<td>in UTI.</td>
<td></td>
</tr>
<tr>
<td>Amendment no/date.</td>
<td>13/06.06.17</td>
</tr>
<tr>
<td>Issue no. discarded.</td>
<td>8.1</td>
</tr>
<tr>
<td>Insert issue no.</td>
<td>8.2</td>
</tr>
<tr>
<td><strong>Section(s) involved</strong></td>
<td>Amendment</td>
</tr>
<tr>
<td>Introduction.</td>
<td>Definition of pyuria added and</td>
</tr>
<tr>
<td></td>
<td>referenced.</td>
</tr>
<tr>
<td>Appendix 2.</td>
<td>Formula and definitions updated.</td>
</tr>
<tr>
<td>Amendment no/date.</td>
<td>12/06.09.16</td>
</tr>
<tr>
<td>Issue no. discarded.</td>
<td>8</td>
</tr>
<tr>
<td>Insert issue no.</td>
<td>8.1</td>
</tr>
<tr>
<td><strong>Section(s) involved</strong></td>
<td>Amendment</td>
</tr>
<tr>
<td>Types of urine specimen and</td>
<td>Spelling error corrected.</td>
</tr>
<tr>
<td>collection.</td>
<td></td>
</tr>
<tr>
<td>Amendment no/date.</td>
<td>11/15.08.16</td>
</tr>
<tr>
<td>Issue no. discarded.</td>
<td>7.2</td>
</tr>
<tr>
<td>Insert issue no.</td>
<td>8</td>
</tr>
<tr>
<td><strong>Section(s) involved</strong></td>
<td>Amendment</td>
</tr>
</tbody>
</table>
### Investigation of urine

<table>
<thead>
<tr>
<th>Section</th>
<th>Updates/Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Introduction.</strong></td>
<td>This has been expanded to include pyuria, haematuria, and Candida species. The section has been streamlined to make it easier to find information that relates to men and women. Healthcare associated UTI has now been changed to ‘Catheterisation’. The section on semi-automated methods has been expanded to include more systems. Legionella urinary antigen detection has been added to the document. Screening for <em>Neisseria gonorrhoea</em> has been added.</td>
</tr>
<tr>
<td><strong>Technical information/limitations.</strong></td>
<td>“Transport of urine specimens” section has been expanded. Section on “Validation and verification” has been added. Section on “Carry over contamination” has been added.</td>
</tr>
<tr>
<td><strong>Antimicrobial susceptibility testing.</strong></td>
<td>This section has been expanded and now includes a reporting table.</td>
</tr>
<tr>
<td><strong>Reporting procedure.</strong></td>
<td>Two new sections have been added to this; “Microscopy or chemical screening reporting times” and “Urine for antigen testing”. Note for <em>T. hominis</em> removed.</td>
</tr>
</tbody>
</table>
**UK SMI##: scope and purpose**

**Users of SMIs**

Primarily, SMIs are intended as a general resource for practising professionals operating in the field of laboratory medicine and infection specialties in the UK. SMIs also provide clinicians with information about the available test repertoire and the standard of laboratory services they should expect for the investigation of infection in their patients, as well as providing information that aids the electronic ordering of appropriate tests. The documents also provide commissioners of healthcare services with the appropriateness and standard of microbiology investigations they should be seeking as part of the clinical and public health care package for their population.

**Background to SMIs**

SMIs comprise a collection of recommended algorithms and procedures covering all stages of the investigative process in microbiology from the pre-analytical (clinical syndrome) stage to the analytical (laboratory testing) and post analytical (result interpretation and reporting) stages. Syndromic algorithms are supported by more detailed documents containing advice on the investigation of specific diseases and infections. Guidance notes cover the clinical background, differential diagnosis, and appropriate investigation of particular clinical conditions. Quality guidance notes describe laboratory processes which underpin quality, for example assay validation.

Standardisation of the diagnostic process through the application of SMIs helps to assure the equivalence of investigation strategies in different laboratories across the UK and is essential for public health surveillance, research and development activities.

**Equal partnership working**

SMIs are developed in equal partnership with PHE, NHS, Royal College of Pathologists and professional societies. The list of participating societies may be found at [https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories](https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories). Inclusion of a logo in an SMI indicates participation of the society in equal partnership and support for the objectives and process of preparing SMIs. Nominees of professional societies are members of the Steering Committee and Working Groups which develop SMIs. The views of nominees cannot be rigorously representative of the members of their nominating organisations nor the corporate views of their organisations. Nominees act as a conduit for two way reporting and dialogue. Representative views are sought through the consultation process. SMIs are developed, reviewed and updated through a wide consultation process.

**Quality assurance**

NICE has accredited the process used by the SMI Working Groups to produce SMIs. The accreditation is applicable to all guidance produced since October 2009. The process for the development of SMIs is certified to ISO 9001:2008. SMIs represent a good standard of practice to which all clinical and public health microbiology laboratories in the UK are expected to work. SMIs are NICE accredited and represent

---

6 Microbiology is used as a generic term to include the two GMC-recognised specialties of Medical Microbiology (which includes Bacteriology, Mycology and Parasitology) and Medical Virology.
neither minimum standards of practice nor the highest level of complex laboratory investigation possible. In using SMIs, laboratories should take account of local requirements and undertake additional investigations where appropriate. SMIs help laboratories to meet accreditation requirements by promoting high quality practices which are auditable. SMIs also provide a reference point for method development. The performance of SMIs depends on competent staff and appropriate quality reagents and equipment. Laboratories should ensure that all commercial and in-house tests have been validated and shown to be fit for purpose. Laboratories should participate in external quality assessment schemes and undertake relevant internal quality control procedures.

**Patient and public involvement**

The SMI Working Groups are committed to patient and public involvement in the development of SMIs. By involving the public, health professionals, scientists and voluntary organisations the resulting SMI will be robust and meet the needs of the user. An opportunity is given to members of the public to contribute to consultations through our open access website.

**Information governance and equality**

PHE is a Caldicott compliant organisation. It seeks to take every possible precaution to prevent unauthorised disclosure of patient details and to ensure that patient-related records are kept under secure conditions. The development of SMIs are subject to PHE Equality objectives [https://www.gov.uk/government/organisations/public-health-england/about/equality-and-diversity](https://www.gov.uk/government/organisations/public-health-england/about/equality-and-diversity).

The SMI Working Groups are committed to achieving the equality objectives by effective consultation with members of the public, partners, stakeholders and specialist interest groups.

**Legal statement**

While every care has been taken in the preparation of SMIs, PHE and the partner organisations, shall, to the greatest extent possible under any applicable law, exclude liability for all losses, costs, claims, damages or expenses arising out of or connected with the use of an SMI or any information contained therein. If alterations are made by an end user to an SMI for local use, it must be made clear where in the document the alterations have been made and by whom such alterations have been made and also acknowledged that PHE and the partner organisations shall bear no liability for such alterations. For the further avoidance of doubt, as SMIs have been developed for application within the UK, any application outside the UK shall be at the user’s risk.

The evidence base and microbial taxonomy for the SMI is as complete as possible at the date of issue. Any omissions and new material will be considered at the next review. These standards can only be superseded by revisions of the standard, legislative action, or by NICE accredited guidance.

SMIs are Crown copyright which should be acknowledged where appropriate.

**Suggested citation for this document**

Scope of document

Type of specimen
Bag urine, pad urine, catheter urine, prostate massage/secretions, clean catch urine, suprapubic aspirate, cystoscopy urine, ureteric urine, ileal conduit urine, urostomy urine, mid-stream urine, nephrostomy urine

This SMI describes the processing and bacteriological investigation of urine samples. These include mid-stream and clean catch specimens and those collected via bag, ileal conduit, ureter, catheter, urostomy, nephrostomy, cystoscopy, suprapub ic aspirate, prostate massage/secretions, and pad urine.

This SMI does not describe in detail semi-automated systems such as urine analysers which should be validated and used in accordance with manufacturers’ instructions. Due regard should be taken of various groups including pregnant women, children, men and all patients who are immunocompromised.

This SMI also covers the detection of Legionella urinary antigens.

This SMI should be used in conjunction with other SMIs.

Introduction

Urinary tract infection
Urinary tract infection (UTI) results from the presence and multiplication of microorganisms, in one or more structures of the urinary tract, with associated tissue invasion. This can give rise to a wide variety of clinical syndromes. These include acute and chronic pyelonephritis (kidney and renal pelvis), cystitis (bladder), urethritis (urethra), epididymitis (epididymis) and prostatitis (prostate gland). Infection may spread to surrounding tissues (eg perinephric abscess) or to the bloodstream.

Protection against infection is normally given by the constant flow of urine and regular bladder emptying. Urine is a poor culture medium for many bacteria due to its acidity, high urea concentration and variable osmolality and, in men, possibly partly as a result of antibacterial activity of prostatic secretions.

The following is a list of terms used in UTI:

Bacteriuria
Bacteriuria implies that bacteria are present and may be cultured from urine. The patient may or may not be symptomatic.

Pyuria is defined as the presence of 10 or more white blood cells per cubic millimetre in a urine specimen, 3 or more white cells per high-power field of unspun urine, a positive result on Gram's staining of an unspun urine specimen, or a urinary dipstick test that is positive for leucocyte esterase. It is most commonly associated with a bacterial urinary tract infection in the upper or lower urinary tract. Pyuria may be present in septic patients, or in older patients with pneumonia.

Other conditions that could cause pyuria are infections (such as that caused by C. trachomatis, N. gonorrhoeae, or herpes simplex virus and occasionally in women with vaginitis caused by T. vaginalis or candida infections), pyelonephritis, papillary necrosis, diabetes, renal tuberculosis, renal stones, Kawasaki disease and cancer.
Sterile Pyuria (ie no growth on routine culture media and the persistent presence of white blood cells in the urine) may be the result of many factors including: a result of prior treatment with antimicrobial agents; catheterisation; calculi (stones); or bladder neoplasms. Other conditions which may lead to sterile pyuria include genital tract infection; sexually transmitted diseases, eg C. trachomatis or an infection with a fastidious organism\textsuperscript{7,8}. Renal tuberculosis may also be implicated in sterile pyuria but is uncommon, although should be considered if clinically indicated (eg in high risk populations\textsuperscript{9}).

Haematuria\textsuperscript{10} – Haematuria is observed in patients with acute cystitis, but is rarely seen in association with other dysuric syndromes. Finding 1–2 red blood cells (RBCs)/high power field is not considered to be abnormal. Haematuria may be caused by non-infective pathological conditions of the urinary tract or by renal mycobacterial infection, with or without associated pyuria. Apparent haematuria may be the result of menstruation. Differentiation of dysmorphic RBCs to determine those of glomerular origin is sometimes requested by specialist units, although its reliability is disputed\textsuperscript{11,12}. RBC lysis may occur in hypertonic and hypotonic urine, rendering them undetectable by microscopy.

Symptomatic patients
Symptomatic patients may be bacteriuric or abacteriuric. Symptoms in children and the elderly, when present, may be non-specific and difficult to interpret.

Frequency
The average bladder capacity is about 500mL. Significant reduction in capacity accompanies acute inflammation which can lead to an increase in the frequency of micturition.

Dysuria
Dysuria is painful and difficult micturition.

Urgency
Urgency is a strong desire to empty the bladder, which can lead to incontinence.

Nocturia
Nocturia is waking in the night one or more times to void the bladder\textsuperscript{13,14}. Nocturnal enuresis is the involuntary voiding of urine during sleep, ie bed-wetting.

Incontinence
Incontinence is the involuntary leakage of urine. The commonest form of this is stress incontinence where leakage accompanies an increase in intra-abdominal pressure due to sneezing, coughing or laughing. Overflow or dribbling incontinence accompanies an overfilled bladder.

Renal colic
This is characterised by very severe cramping pain resulting from distension of the ureter and pelvis above an obstruction such as a renal stone. Often accompanied by frequency and urgency.
Clinical manifestations of UTI

Asymptomatic bacteriuria and candiduria
Asymptomatic bacteriuria is common in several patient groups, particularly the elderly, pregnant women, transplant patients and diabetic patients\(^\text{15-17}\).

Acute urethral syndrome
Acute urethral syndrome occurs in women with acute lower urinary tract symptoms with either a low bacterial count or without demonstrable bacteriuria or vulvovaginal infection\(^\text{7,18}\). The condition can also occur in men but is not well studied\(^\text{19}\).

Uncomplicated UTI
Uncomplicated UTI occurs in otherwise healthy individuals. There are no underlying structural or neurological lesions of the urinary tract, and no other systemic diseases predisposing the host to bacterial infection. Recurrences are usually reinfections with organisms ascending via the urethra.

Acute uncomplicated cystitis
Acute uncomplicated cystitis condition usually occurs in young women. It has an abrupt onset and produces severe symptoms which are usually accompanied by pyuria and bacteriuria. Uncomplicated cystitis can occur in some men\(^\text{20}\).

Complicated UTI
Complicated UTI occurs in patients in whom there may be residual inflammatory changes following recurrent infection or instrumentation, obstruction, stones, or anatomical or physiological abnormalities or pathological lesions. These interfere with drainage of urine in part of the tract which encourages prolonged colonisation. Relapses with the same organism may occur.

The following are examples of complicated UTI:

Acute pyelonephritis (pyelitis) – An inflammatory process of the kidneys and adjacent structures. Symptoms include loin, low back or abdominal pain and fever. Symptoms of cystitis may also be present. Severity ranges from mild disease to full blown Gram negative sepsis.

Chronic pyelonephritis (chronic interstitial nephritis, or reflux nephropathy) – Controversy exists over the definition and cause of this syndrome. It is the second most common cause of end-stage renal failure. It is thought to be a result of renal damage caused by UTI in infants and children with vesicoureteric reflux, or by obstructive uropathy in adults. However, it is still unclear whether recurrent infection causes progressive kidney damage.

Perinephric abscess – A complication of UTI, although uncommon, that affects patients with one or more anatomical or physiological abnormalities. The abscess may be confined to the perinephric space or extend into adjacent structures. Pyuria, with or without positive culture, is seen on examination of urine, but is not always present. Causative organisms are usually Gram negative bacilli, but can also be staphylococci or Candida species. Mixed infections have also been reported.

Prostatitis\(^\text{21,22}\) – An inflammatory condition of the prostate gland that occurs in a variety of different forms, some involving infection. Routes of infection of the prostate include ascending urethral infection, reflux of infected urine into the prostatic ducts.
Investigation of urine

that empty into the posterior urethra, invasion of rectal bacteria by direct extension, or by lymphatic or haematogenous spread.

Types of prostatitis include:

- **acute bacterial prostatitis** – An abrupt, febrile illness with marked constitutional and genitourinary symptoms.

- **chronic bacterial prostatitis** – Relapsing and recurrent UTIs, caused by the organisms persisting in the prostatic secretions despite antimicrobial therapy. The method of Meares and Stamey compares white blood cell (WBC) and bacterial counts of urethral, mid-stream and post-prostatic massage urine specimens, and expressed prostatic secretions (EPS). Prostatic massage should not be undertaken in patients with acute prostatitis because of the risk of precipitating bacteraemia. All specimens are taken at the same time and processed immediately. Chronic bacterial prostatitis is less common than non-bacterial prostatitis. Bacterial prostatitis is associated with UTI. Organisms responsible are similar to those that cause UTI.

Pyonephrosis – The bacterial infection of an obstructed ureter which fills with pus. This may follow surgical intervention. Diagnosis is made from blood culture or pus drained from the kidney.

Renal abscesses – Localised in the renal cortex and may occur as a result of bacteraemia. Pyuria may also be present, but urine culture is usually negative. Renal abscesses are increasingly being seen as complications of acute pyelonephritis caused by Gram negative bacilli. The rare condition of emphysematous pyelonephritis, which results in multifocal intrarenal abscesses and gas formation within the renal parenchyma, is usually seen in diabetic patients or as a complication of renal stones. *Escherichia coli* is the commonest cause.

Urethritis – Common in both male and female patients, and is often associated with UTI or occasionally with bacterial prostatitis.

In men, urethritis is commonly caused by sexually transmitted diseases and is associated with urethral discharge. The main organisms responsible are: *Neisseria gonorrhoeae* (gonococcal urethritis), *Chlamydia trachomatis* and *Mycoplasma genitalium* (non-gonococcal urethritis or NGU).

In female patients the condition may appear as acute urethral syndrome or urethrocystitis caused by Enterobacteriaceae, *Staphylococcus saprophyticus*, and less commonly by *C. trachomatis* and *N. gonorrhoeae*.

**Incidence of UTI**

The incidence of UTIs is influenced by age, sex or by predisposing factors that may impair the wide variety of normal host defence mechanisms.

**Children**

UTI is a common bacterial infection that causes illness in children, in whom it may be difficult to diagnose as the presenting symptoms are often non-specific. In children, the condition is often associated with renal tract abnormalities and is most common in males in the first three months of life as a result of congenital abnormalities. In older children, females are more commonly affected. Infection in preschool boys is often associated with renal tract abnormality. Failure to diagnose and treat UTI quickly and effectively may result in renal scarring and ultimately loss of
function. The phenomenon of vesicoureteric reflux, while predisposing children to UTI, may also be caused by UTI26-29.

Confirmation of UTI in children is dependent on the quality of the specimen, which is often difficult to obtain cleanly. The probability of UTI is increased by the isolation of the same organism from two specimens.

Colony counts of $\geq 10^6$ cfu/L ($10^3$ cfu/mL) of a single species may be diagnostic of UTI in voided urine. Generally, a pure growth of between $10^7$-$10^8$ cfu/L ($10^4$-$10^5$ cfu/mL) is indicative of UTI in a carefully taken specimen.

Negative cultures or growth of $<10^7$ cfu/L ($<10^4$ cfu/mL) from bag urine may be diagnostically useful. Counts of $\geq 10^8$ cfu/L ($\geq 10^5$ cfu/mL) should be confirmed by culture of a more reliable specimen, either a single urethral catheter specimen or, preferably, an SPA.

Bacteriuria usually exceeds $\geq 10^8$ cfu/L ($\geq 10^5$ cfu/mL) in SPAs from children with acute UTI, although any growth is potentially significant.

**Adults**

**Women**

The incidence of UTI is highest in young women. Around 10–20% of women will experience a symptomatic UTI at some time. In acutely symptomatic women, UTI may be associated with counts of a single isolate as low as $10^5$ cfu/L ($10^2$ cfu/mL) in voided urine30,31. Interpretation of culture results must be made with care however, and take into account factors such as age and storage of specimen, level of contamination indicated by SECs, and the sensitivity of the method.

Growths of $<10^8$ cfu/L ($<10^5$ cfu/mL) in asymptomatic, non-pregnant women are rarely persistent and usually represent contamination.

**Men**

Most infections in adult men are complicated and related to abnormalities of the urinary tract, although a low incidence occurs spontaneously in otherwise healthy young men.

Counts as low as $10^6$ cfu/L ($10^3$ cfu/mL) of a pure or predominant organism have been shown to be significant in voided urine from men32. Where there is evidence of contamination, a carefully collected repeat specimen should be examined.

**The elderly**

UTI incidence increases with age for both sexes and is one of the most common infections associated with this age group33-35. It is estimated that 10% of males and 20% of females over the age of 80 have asymptomatic bacteriuria36. Underlying health issues can make this condition particularly difficult to diagnosis and prone to resistant strains. According to some, no treatment is indicated for asymptomatic patients except before invasive genitourinary procedures.
Pregnancy
Studies in the UK have shown that asymptomatic bacteriuria (persistent colonisation of the urinary tract without urinary symptoms) occurs in 4% of pregnant women\(^37\). Unless detected and treated early, there is an increased risk of preterm birth and pyelonephritis affecting maternal and fetal outcome. In about 30% of patients acute pyelonephritis occurs, especially at the time of delivery\(^38,39\). It has been reported that 20–40% of pregnant women with untreated bacteriuria will develop pyelonephritis\(^38\).

In pregnancy, routine and sensitive urinary screening programmes are essential for the detection of bacteriuria in pregnancy. The screening can be done by mid-stream urine culture early in pregnancy. The presence of \( \geq 10^8 \text{ cfu/L} \) (\( \geq 10^5 \text{ cfu/mL} \)) in asymptomatic, pregnant women indicates infection but should be confirmed in a repeat sample\(^40\).

Diabetes
Women with diabetes have a higher incidence of asymptomatic bacteriuria than those without\(^41,42\). There is no difference in the prevalence of bacteriuria between men with diabetes, and men without diabetes\(^42\). There is a debate as to whether factors such as glycosuria, age or instrumentation are contributory to the high prevalence of UTI, but bladder dysfunction as a result of diabetic neuropathy may be the major predisposing factor\(^41\). The relative incidences of symptomatic infection in patients with or without diabetes remain unclear but, when they do occur, UTIs tend to be more severe in patients with diabetes\(^43,44\).

Neuromuscular disorders
Patients with impaired bladder innervation as a result of congenital or acquired disorders (spina bifida, spinal cord injury) are at increased risk of UTI and it can be a significant cause of death\(^45\). This may be due to impaired function of the bladder leading to incomplete emptying, or an increased requirement for instrumentation of the urinary tract to assist voiding.

Renal transplantation\(^46-48\)
Most infections occur soon after transplantation, usually as a result of catheterisation, the presence of a ureteric drainage tube, or a previous UTI whilst on dialysis. Less commonly, infection may be introduced via the donor kidney.

Immunosuppression
Overall the incidence of UTI is not higher in patients who are immunocompromised compared with those who are not. The exceptions to this include patients who are diabetic or have undergone renal transplants\(^49\). There have also been studies that suggest that men who are suffering from acquired immunodeficiency syndrome (AIDS) may also be at increased risk from bacteriuria, and symptomatic UTI; with severe episodes resulting in bloodstream infection and death being reported\(^50\). However, because of long-term antibiotic use for other infections, UTI in such patients is often due to more unusual or resistant organisms. Steroid treatment may induce reactivation of tuberculosis of the urinary tract.

Catheterisation
Catheter acquired urinary tract infections is one of the most common health care acquired infections\(^51\). However samples from patients with indwelling catheters may
not accurately reflect the true bladder pathogen and often contains several bacterial species. Culture results should be interpreted with caution. The criteria have not been established for differentiating asymptomatic colonisation of the urinary tract from symptomatic infection\(^5\). Urine cultures may not reflect bladder bacteriuria because sampled organisms may have arisen from biofilms on the inner surface of the catheter\(^5\). Therefore the quality of the specimen collected and clinical circumstances in the individual patient are critical in the interpretation of bacterial counts. In carefully collected specimens, taken under controlled study conditions in short term catheterised patients, counts of \(<10^8\) cfu/L \(<10^5\) cfu/mL have been shown to be significant\(^5\). In specimens of unknown quality and those from long term-catheterised patients, interpretation of significance on the basis of bacterial counts alone may be impossible. Significance of isolates and reporting of sensitivities may be indicated in certain groups – such as urology or post-operative patients, especially if future operative intervention is planned on the urinary tract.

Bacterial counts from catheterised patients may be affected by the administration of medication or fluids that increase urine flow, rapid transit of urine from the catheterised bladder, or colonisation with relatively slow growing organisms such as *Candida* species\(^5\).

Catheterisation is occasionally used to collect a contamination free sample (‘in and out’) when any bacterial growth is significant. Specimens from patients with intermittent self-catheterisation should be treated as mid-stream urine.

**Organisms implicated in UTI**

**Acute, uncomplicated UTIs**

Acute, uncomplicated UTIs are usually caused by a single bacterial species.

*E. coli* – is the most common organism involved in UTI. An international survey of mid-stream urine (MSU) samples taken at 252 centres in 17 countries reports that *E. coli* accounts for 77% of isolates\(^5\).

Only a few serotypes frequently cause UTI. This might reflect their prevalence in the faecal flora, or reflect differences in virulence factors. Certain virulence factors specifically favour the development of pyelonephritis, whereas others favour cystitis or asymptomatic bacteriuria\(^5\).

*Proteus mirabilis* – Common in young boys and males, and is associated with renal tract abnormalities, particularly calculi. In hospital patients it may cause chronic infections.

*S. saprophyticus* – Studies have shown that this organism was found to be responsible for 4% of UTIs. *S. saprophyticus* adheres to uroepithelial cells significantly better than *S. aureus* or other coagulase negative staphylococci.

**Other coagulase negative staphylococci** – Often considered as urinary contaminants as they are part of the normal perineal flora.

**Streptococci** – Rarely cause uncomplicated UTI, although Lancefield Group B streptococci may cause infection in some women. Enterococci may occasionally cause uncomplicated UTI.

**Candida species** - is associated with indwelling catheters, but may also be present as contamination from the genital tract. *Candida albicans* is the most frequently isolated species.
Complicated UTIs
Complicated UTIs which occur in the abnormal or catheterised urinary tract are caused by a variety of organisms, many of them with increased antimicrobial resistance as a result of the prolonged use of antibiotics.

*E. coli* remains the most common isolate. Other frequent isolates include *Klebsiella*, *Enterobacter* and *Proteus* species, *Enterococcus* species (usually associated with instrumentation and catheterisation), and *Pseudomonas aeruginosa* (associated with structural abnormality or permanent urethral catheterisation). *S. aureus* rarely causes infection, and is associated with renal abnormality or as a secondary infection to bacteraemia, surgery or catheterisation. It is frequently seen as a contaminant due to perineal carriage. Other coagulase negative Staphylococci may cause complicated infections in patients of both sexes with structural or functional abnormalities of the urinary tract, prostatic calculi or predisposing underlying disease.

**Types of urine specimen and collection**

**Midstream urine (MSU) and clean-catch urine**
MSU and clean catch urines are the most commonly collected specimens and are recommended for routine use. Cleaning the area before sampling makes little difference to contamination rates.

**Suprapubic aspirate (SPA)**
Suprapubic aspirate (SPA) is seen as the ‘gold standard’ but is usually reserved for clarification of equivocal results from voided urine in infants and small children. Before SPA is attempted it is preferable to use ultrasound guidance to determine the presence of urine in the bladder.

**Catheter urine (CSU)**
‘In and out’, or intermittent self-catheterisation, samples are occasionally collected to ensure that they are contamination free.

**Bag and pad urine**
Bag urine is commonly collected from infants and young children, although it should be discouraged as pads are a more comfortable and easier method of collection. Artificially elevated leucocyte counts may be seen as a result of vaginal reflux of urine, recent circumcision or confusion with round epithelial cells found in urine from neonates. Negative cultures provide useful diagnostic information, but significant growth should be confirmed with SPA.

**Other specimens**
Other specimens obtained during or as a result of surgery include those from ileal conduit, cystoscopy, nephrostomy and urostomy, prostatic massage/secretions. Specimens may also be taken after bladder washout.

**Laboratory investigation of UTI**
Laboratory investigation of UTI normally involves microscopy (or an alternative method of measuring cellular components) and quantitative culture (or an alternative non-culture method such as a semi-automated urine analyser) with the use of chemical screening methods in certain instances.
The three main methods for the detection of UTIs involve culture, non-culture semi-automated systems (e.g., particle counting, electrical impedance, colorimetric filtration, photometry, bioluminescence, radiometry) and chemical (e.g., leucocyte esterase, nitrite, protein, and blood detection):

Except in a few patient groups, interpretations of culture results are made with regard to clinical presentation, the presence or absence of pyuria (which are associated with infection) and squamous epithelial cells (SECs) (which indicate contamination).

A reference guide for the diagnosis of UTI is available for use by clinicians. Clinical evaluation of the patient helps the interpretation of laboratory results and assists in the diagnosis of UTI.

Adequate internal control measures are critical, especially when chemical tests are deployed away from the laboratory near to the patient and where culture is not performed on the basis of negative results.

**Microscopy**

Microscopy is used to identify the presence of white blood cells (WBCs), RBCs, casts, SECs, bacteria and other cellular components in the urine. Semi-quantitative methods using a microtitre tray with an inverted microscope or a disposable counting chamber are recommended for routine use. This SMI contains a table of multiplicative factors based on the varying volumes of urine dispensed, the diameter of well and the field of vision diameter (refer to Appendix 1 and 2).

Microscopy need not be performed on all urine samples where screening for asymptomatic bacteriuria is required (e.g., antenatal clinic screening) and may be omitted for such indications if in compliance with local protocols. Automated screening systems offer flexible, cost-effective alternatives to microscopy. Microscopy (or an alternative) is recommended for all symptomatic patient groups, to assist in the interpretation of culture results and the diagnosis of UTI.

Microscopy of uncentrifuged, unstained urine has been used as a method of screening for bacteriuria without the need for culture, but is unreliable to detect counts <10^7 colony forming units per litre (cfu/L), i.e., <10^4 colony forming units per millilitre (cfu/mL). The sensitivity increases if the specimen is centrifuged and/or stained.

In a carefully taken specimen, significant pyuria correlates well with bacteriuria and symptoms in most patients to suggest a diagnosis of UTI. Significant pyuria is defined as the occurrence of 10^7 or more WBC/L (10^4 WBC/mL), although higher numbers of WBC are often found in healthy asymptomatic women. A level of >10^8 WBC/L (>10^5 WBC/mL) has been suggested as being more appropriate in discriminating infection.

**RBCs** - Laboratories should consult with local urologists regarding the reporting of RBCs in urine.

**Casts** – Casts are cylindrical protein mouldings formed in the renal tubules and often giving clues to renal pathology. Recognition of casts is important in helping to establish the existence of renal disease, but is less useful in the differentiation of renal disorders.

Large numbers of hyaline casts are associated with renal disease, but may also be found in patients with fever or following strenuous exercise. Cellular and densely granular casts indicate pyelonephritis or glomerulonephritis. RBC casts usually indicate glomerular bleeding and are excreted in large numbers in the acute phase of
post-streptococcal nephritis or rapidly progressive nephritis. Less commonly, epithelial cell and fatty casts accompany acute tubular necrosis and nephrotic syndrome.

**Crystals** – These may be asymptomatic or associated with the formation of urinary tract calculi. Some crystals such as cystine are rarely seen and may indicate an underlying metabolic disease.

**Squamous epithelial cells** – SECs are a useful indicator of the degree of contamination from the perineal region.

**Non-culture methods**

**Semi-automated methods**

Urine analyser systems are expensive and vary in their performance. They are intended to identify red and white blood cells, bacteria, yeasts, epithelial cells, mucus, sperm, crystals and casts (depending on the technology).

Urine analysers may be used to screen for 'negatives' to allow earlier reporting and to facilitate cost-effective processing. If urine analysers are used as a screening procedure to reduce the number of urine samples set up for culture, then there is a need for a robust validation and the key performance parameter is sensitivity. The cut-off values of the bacterial and WBC counts used to screen out urines can usually be set by individual users using the Sysmex UF-100 demonstrated that they could achieve a high sensitivity (98%) only at the price of reduced specificity (25%) which meant that only 22% of their urines would not be cultured.

Each laboratory should set cut off values to achieve clinically relevant sensitivity and predictive values appropriate for the key local populations (children, pregnant women and patients who are immunocompromised) and under take appropriate validation and verification.

It may be prudent, regardless of the screening results, to culture all urines from certain patients such as those from children, pregnant women and patients who are immunocompromised. The rationale for this recommendation is that there are more severe consequences in missing infection in children and the potential absence of WBCs in urine from asymptomatic pregnant women or patients who are immunocompromised.

Currently available technologies include the following:

- **flow cytometry**: this works by measuring electrical impedance (for volume), light scatter (for size) and use of fluorescent dyes (for nuclear and cytoplasmic staining). The particles are characterised using these measurements, and the results are displayed as scattergrams. Sensitivity and specificity results can vary depending on the parameters and cut-offs employed. Cut-off criteria are chosen for an analyser to balance the levels of sensitivity and specificity required according to a local assessment of clinical need.

- **particle recognition system**: the urine specimen passes through the analyser and a camera captures up to 500 frames per specimen. Each image is classified by size, shape, contrast and texture features. This technology has been shown to be more reliable for identifying cellular components, but less suitable for detection of bacteriuria. For cases that appear to be borderline manual microscopy counts are still needed.
• microscopic urine sediment analysis: the autoanalyzer will homogenize the specimen and transfer it to a single use cuvette (volume aspirated: 2.0 ml, volume examined: 2.2 µl) which are centrifuge for few seconds. Afterwards, whole-field high definition images are obtained (15 per sample) and the software (Auto Image Evaluation Module AIEM) performs a morphological analysis of the particles, allowing them to be counted and classified²⁷.

**Chemical screening tests**

Non-culture chemical screening tests may be used for screening negative urines according to selected criteria⁷⁸-⁸¹. Most chemical tests are available commercially as dipsticks and are quick and easy to use. Reading colour changes in dipstick strips using colorimetric measurement is preferred, as results are more reliable and reproducible, and free from observer error, particularly if an automated reading system is used⁸²,⁸³. Boric acid, and some antimicrobial agents such as nitrofurantoin, and gentamicin adversely affect the leucocyte esterase test.

Chemical tests for the presence of blood may be more sensitive than microscopy as a result of the detection of haemoglobin released by haemolysis. The absence of all four infection associated markers (blood, leucocyte esterase, nitrate and protein) had a greater than 98% negative predictive value and a sensitivity and specificity of 98.3% and 19.2% respectively according to one study⁸⁰.

**Culture methods**

There are several culture methods for the quantification of bacteria in urine. The easiest and most commonly used are the calibrated loop technique, the sterile filter paper strip and multipoint technology⁸⁴-⁸⁶. Of these, multipoint methodology using CLED or chromogenic media, are considered to be the most versatile and efficient for large numbers of specimens. Other methods include use of dipslides, pour plates and roll tubes. These methods are not recommended for routine use in this SMI but may be useful in specific circumstances and in accordance with local protocols.

Multipoint inoculation of CLED agar alone may contribute to the under reporting of mixed cultures that are more readily identified using chromogenic agar or a range of identification and susceptibility media. The culture of urine by multipoint methods may be automated, or performed manually using either microtite trays containing agar or by using 9mm agar plates. Microtite trays may be read manually or with an automated system where the resulting data are transferred to the laboratory information management system for reporting. Microtite trays examined manually require background light and some form of magnification to facilitate the recognition of mixed cultures and small colonies.

Chromogenic media contain various substrates which permit presumptive identification of several common species through a change in either colony pigmentation or colour of agar. They perform satisfactorily compared to CLED and have the advantage that mixed cultures are easier to detect. However, chromogenic media from different manufacturers can vary in specificity, and are relatively expensive⁸⁴,⁸⁷.

The use of agar plates (rather than microtite trays) may lead to false negative reporting if antimicrobial substances present in some urines diffuse to neighbouring inocula. When this occurs, repeat culture of the affected inocula is required.
**Interpretation of culture**

Studies conducted in the 1950s remain the basis for interpreting urine culture results showing that bacterial counts of $\geq 10^8$ cfu/L ($\geq 10^5$ cfu/mL) are indicative of an infection and counts below this usually indicate contamination\(^8\). The most common organism implicated in UTI in this group is *E. coli*\(^{26}\).

In specific patient groups, counts between $10^8$ cfu/L ($10^5$ cfu/mL) and $10^5$ cfu/L ($10^2$ cfu/mL) may be significant\(^{24,30,31}\). A pure isolate with counts between $10^7$ and $10^8$ cfu/L ($10^4$-$10^5$ cfu/mL) should be evaluated based on clinical information or confirmed by repeat culture. Overall, the confirmation of a UTI requires the demonstration of significant bacteriuria by quantitative culture (defined according to patient group or specimen type). Routine culture methods may not be sensitive enough to detect low bacteria levels (eg $\leq 10^7$ cfu/L / $\leq 10^4$ cfu/mL) and increased sensitivity will be achieved by increasing the inoculum size (see section 4.5.2).

Increased inoculum sizes are also required for persistently symptomatic patients without bacteriuria if the patient has recurrent “sterile pyuria”, or for specimens where lower counts are to be expected, such as SPAs or other surgically obtained urine.

**Other urine investigations**

**Screening for antimicrobial substances**

This may be useful to detect false negative cultures where the inoculum contains an antimicrobial agent which diffuses into the agar and inhibits bacterial growth. Where microtitre trays are used for multipoint culture the highest concentration of antimicrobial is localised to the small area of medium in the microtitre tray. Where agar plates are used for multipoint culture (rather than microtitre trays), both the primary and neighbouring inocula, may be affected as a result of the diffusion through the medium.

A seeded plate is inoculated after other plates and the absence of growth after incubation indicates the presence of an antimicrobial substance. The procedure is simple if multipoint replicating devices are used (see section 4.5.2) and may reduce further testing of the specimen (eg for fastidious organisms)\(^{89}\).

**Detection of urinary antigen for Legionella**

Urinary antigen (UrAg) detection is a convenient and cost-effective method of diagnosing Legionnaires’ disease\(^9\). Antigen becomes detectable soon after onset of symptoms and the test may remain positive for several weeks, even after other tests have become negative\(^{91,92}\). The majority of UrAg-positive cases have been found to be a result of infection from *L. pneumophila* serogroup 1\(^{93}\). Equivocal EIA results should be examined by a second person and repeated for serogroup 1\(^{94}\).

**Note:** The UrAG test may not be appropriate in cases of nosocomial or atypical pneumonia.

Where practical, respiratory samples should be obtained from all patients with positive Legionella urinary antigen tests, and these, (and culture isolates if available), should be sent to the reference laboratory for strain typing.

A sample should be retained at -20°C in the event that re-testing may be required because of legal action (take care to ensure preservation of the chain of evidence)\(^{95}\).
Screening for *Salmonella Typhi* and *Salmonella Paratyphi*

*S. Typhi* and *S. Paratyphi* are present in urine in the early stages of typhoid and paratyphoid fever. Screening urines may be received from suspected cases and/or their contacts for selective enrichment and culture.

**Diagnosis of *Schistosoma haematobium* infection**

May be undertaken on urine taken at a specific time coinciding with maximum egg excretion, or on the terminal portion of voided urine. Haematuria is the most common presentation of *S. haematobium* infection. Chronic infection can lead to bladder cancer (see B 31 – *Investigation of specimens other than blood for parasites*).

**Screening for *Chlamydia trachomatis* and *Neisseria gonorrhoea***

May be undertaken on urine specimens from patients with sterile pyuria or as part of investigation for infection with sexually transmitted disease.

**Technical information/limitations**

**Limitations of UK SMI**

The recommendations made in UK SMI are based on evidence (e.g., sensitivity and specificity) where available, expert opinion and pragmatism, with consideration also being given to available resources. Laboratories should take account of local requirements and undertake additional investigations where appropriate. Prior to use, laboratories should ensure that all commercial and in-house tests have been validated and are fit for purpose.

**Selective media in screening procedures**

Selective media which does not support the growth of all circulating strains of organisms may be recommended based on the evidence available. A balance therefore must be sought between available evidence, and available resources required if more than one media plate is used.

**Specimen containers**

SMI use the term, “CE marked leak proof container,” to describe containers bearing the CE marking used for the collection and transport of clinical specimens. The requirements for specimen containers are given in the EU in vitro Diagnostic Medical Devices Directive (98/79/EC Annex 1 B 2.1) which states: “The design must allow easy handling and, where necessary, reduce as far as possible contamination of and leakage from, the device during use and, in the case of specimen receptacles, the risk of contamination of the specimen. The manufacturing processes must be appropriate for these purposes.”

**Transport of urine specimens**

Rapid transport, culture, or measures to preserve the sample aid reliable laboratory diagnosis. Delays and storage at room temperature allow organisms to multiply, which generate results that do not reflect the true clinical situation. Where delays in processing are unavoidable, refrigeration at 4°C is recommended or the use of a boric acid preservative may be beneficial.
Boric acid preservative at a concentration of 1–2% holds the bacterial population steady for 48–96 hours, and other cellular components remain intact\textsuperscript{98,99}. Toxicity to certain organisms has been reported\textsuperscript{100}. The toxic effect is delayed and often reflects underfilling of the container\textsuperscript{101,104}.

Boric acid increases the maximum permissible time for transport to the laboratory to up to 96hr\textsuperscript{105}.

It should be noted that boric acid may be inhibitory to some organisms and may inhibit tests for leucocyte esterase\textsuperscript{99-101}.

**Note:** It is essential to follow the manufacturer’s instructions on sample volume in boric acid containers\textsuperscript{104}.

### SI unit nomenclature

Although SI units have been adopted in other SMIs, they have been left as optional for urines. Most current literature still refer to the old nomenclature when defining ‘significant bacteriuria’. The following is a list of metric units and their SI equivalents.

- $\geq 10^5$ cfu/mL equivalent to $\geq 10^8$ cfu/L
- $< 10^5$ cfu/mL equivalent to $< 10^8$ cfu/L
- $10^4$ cfu/mL equivalent to $10^7$ cfu/L
- $< 10^4$ cfu/mL equivalent to $< 10^7$ cfu/L
- $10^3$ cfu/mL equivalent to $10^6$ cfu/L
- $< 10^3$ cfu/mL equivalent to $< 10^6$ cfu/L
- $10^2$ cfu/mL equivalent to $10^5$ cfu/L

### Validation and verification

Robust validation of the cut offs is required for your local area and should be carried out.

If urine analysers are used as a screening procedure to reduce the number of urine samples set up for culture, then there is a need for a robust validation and the key performance parameter is sensitivity. The cut-off values of the bacterial and WBC counts used to screen out urines can usually be set by individual users using the Sysmex UF-100 demonstrated that they could achieve a high sensitivity (98%) only at the price of reduced specificity (25%) which meant that only 22% of their urines would not be cultured\textsuperscript{70}.

Each laboratory should set cut off values to achieve clinically relevant sensitivity and predictive values appropriate for the key local populations (children, pregnant women and patients who are immunocompromised) and under take appropriate validation and verification.

### Carry over contamination

Carry-over can be a problem with some automated urine analysers and the potential for this problem should be assessed during the validation and verification of these instruments\textsuperscript{106,107}. There are a number of ways of addressing carry-over concerns such as increasing the number of rinses, but this reduces the throughput; furthermore with one specific analyser even increasing the number of the rinses did not prevent carry-over from specimens with very high bacterial load ($10^7$/mL)\textsuperscript{108}. Other strategies
to reduce the carry-over, or its impact, include taking sample aliquots for culture before submitting the specimens for microscopy or culturing all urines before the microscopy is done, weekly disinfection of the probes with methanol, and regular carry-over tests using boric acid tubes\textsuperscript{106,107}.
1 Safety considerations

1.1 Specimen collection, transport and storage

Use aseptic technique.

Collect specimens in appropriate CE marked leak proof containers and transport in sealed plastic bags.

Compliance with postal, transport and storage regulations is essential.

1.2 Specimen processing

Containment Level 2 unless infection with a Hazard Group 3 organism, for example *Mycobacterium* species, or *Salmonella* Typhi or *Salmonella* Paratyphi A, B and C is suspected.

Where Hazard Group 3 *Mycobacterium* species are suspected, all specimens must be processed in a microbiological safety cabinet under full Containment Level 3 conditions.

Diagnostic work with clinical material that could possibly contain Hazard Group 3 organisms (*Salmonella* Typhi and *Salmonella* Paratyphi A, B & C,) does not normally require full Containment Level 3 containment (paragraph 175).

If these Hazard Group 3 organisms are suspected, work should take place at a higher containment level, but full Containment Level 3 may not be required (paragraphs 179-183).

If the work to be carried out requires the growth or manipulation of a Hazard Group 3 enteric biological agent then this has to be carried out under full Containment Level 3 conditions (paragraph 175).

Note: S. Typhi and S. Paratyphi A, B and C cause severe, sometimes fatal, disease; laboratory acquired infections have also been reported. S. Typhi vaccination is available. Guidance is given in *Immunisation against Infectious Disease* published by Public Health England.

Laboratory procedures that give rise to infectious aerosols must be conducted in a microbiological safety cabinet.

Refer to current guidance on the safe handling of all organisms documented in this SMI.

The above guidance should be supplemented with local COSHH and risk assessments.

2 Specimen collection

2.1 Type of specimens

Bag urine, pad urine, catheter urine, prostate massage/secretions, clean catch urine, suprapubic aspirate, cystoscopy urine, ureteric urine, ileal conduit urine, urostomy urine, mid-stream urine, nephrostomy urine

Urine samples are not suitable for the isolation of leptospires due to the presence of other contaminating bacteria and the poor viability of leptospires in urine.
2.2 Optimal time and method of collection

For safety considerations refer to Section 1.1.

Collect specimens before antimicrobial therapy where possible.

Mid-stream urine (MSU)
MSU is the recommended routine collection method.

The first part of voided urine is discarded and, without interrupting the flow, approximately 10mL is collected into a CE marked leak proof container. The remaining urine is discarded. If boric acid preservative is used, the container is filled up to the mark in a similar manner and the contents mixed well.

Clean-catch urine
A reasonable alternative to MSU.

Periurethral cleaning is recommended. The whole specimen is collected and then an aliquot sent for examination in a CE marked leak proof container.

Suprapubic aspirate (SPA)
Urine is obtained aseptically, directly from the bladder by aspiration with a needle and syringe. The use of this invasive procedure is usually reserved for clarification of equivocal results from voided urine (eg in infants and small children). Ultrasound guidance should be used to show presence of urine in the bladder before carrying out SPA.

Catheter urine (CSU)
The sample may be obtained either from a transient (‘in and out’) catheterisation or from an indwelling catheter. In the latter case, the specimen is obtained aseptically from a sample port in the catheter tubing or by aseptic aspiration of the tubing. The specimen should not be obtained from the collection bag.

Bag urine
Used commonly for infants and young children. The sterile bags are taped over the freshly cleaned and dried genitalia, and the collected urine is transferred to a CE marked leak proof container. There are frequent problems of contamination with this method of collection.

Pad urine
An alternative to collecting bag urine from infants and young children. After washing the nappy area thoroughly, a pad is placed inside the nappy. As soon as the pad is wet with urine (but no faecal soiling), push the tip of a syringe into the pad and draw urine into the syringe. Transfer specimen to a CE marked leak proof container. If difficulty is experienced in withdrawing urine, the wet fibres may be inserted into the syringe barrel and the urine squeezed directly into the container with the syringe plunger.

Ileal conduit – urostomy urine
Urine is obtained via a catheter passed aseptically into the stomal opening after removal of the external appliance. Results from this type of specimen may be difficult to interpret.
Cystoscopy urine
Urine is obtained directly from the bladder using a cystoscope.

Ureteric urine
Urine samples are obtained from one or both ureters during cystoscopy via ureteric catheters inserted from the bladder.
Urine samples may also be sent following nephrostomy, other surgical procedures, or bladder washout.

Meares and Stamey localisation culture method for diagnosis of prostatitis
The following specimens are collected:
- The initial 5–8mL voided urine (urethral urine)
- MSU (bladder urine)
- Expressed prostatic secretions following prostatic massage
- The first 2–3mL voided urine following prostatic massage

Urine for S. Typhi and S. Paratyphi cultures
Any urine samples from suspected cases or contacts of cases.

Early morning urine
Ideally three entire, first voided, early morning urine specimens are needed for culture for M. tuberculosis (see B 40 - Investigation of specimens for Mycobacterium species).

Urine for S. haematobium detection
Total urine sample passed into CE marked leak proof container without boric acid preservative is required. Alternatively, a 24hr collection of terminal urine may be examined (see B 31 - Investigation of specimens other than blood for parasites).

Urine for parasites
For investigation of parasites see B 31 - Investigation of specimens other than blood for parasites.

2.3 Adequate quantity and appropriate number of specimens
A minimum volume of 1mL for specimens in plain CE marked leak proof container for bacterial pathogens.
Fill to the line marked on containers with boric acid preservative according to manufacturers’ instructions.
Numbers and frequency of specimens collected are dependent on clinical condition of patient.

3 Specimen transport and storage
For safety considerations refer to Section 1.1.
Specimens should be transported and processed within 4hr if possible, unless boric acid preservative is used\textsuperscript{102,103}.

If processing is delayed for up to 48hr, refrigeration is essential\textsuperscript{98}. Alternatively, the specimen may be collected in a CE marked leak proof container with boric acid preservative\textsuperscript{99-101,126}.

This increases the maximum permissible time for transport to the laboratory to up to 96hr\textsuperscript{105}.

It should be noted that boric acid may be inhibitory to some organisms and may inhibit tests for leucocyte esterase\textsuperscript{99-101,127}.

Note: It is essential to follow the manufacturer’s instructions on sample volume in boric acid containers\textsuperscript{104}.

### 4 Specimen processing/procedure\textsuperscript{96,97}

#### 4.1 Test selection

Divide specimen on receipt for appropriate procedures such as investigation for viruses (boric acid samples are unsuitable for viruses) and \textit{C. trachomatis} depending on clinical details.

#### 4.2 Appearance

N/A

#### 4.3 Sample preparation

For safety considerations refer to Section 1.2.

#### 4.4 Microscopy or alternative screening methods

##### 4.4.1 Standard

**Microtitre tray with an inverted microscope**

Mix the urine gently, to avoid foaming.

Using a pipette and disposable tips, dispense known volume (~60\(\mu\)L, see ‘Note 2’ below) of mixed urine to a numbered well in a flat-bottomed microtitre tray. Make sure that the specimen covers the whole bottom surface area (the use of a template will facilitate matching the specimen and well number).

Allow to settle for a minimum of 5min, but preferably 10–15min, before reading with an inverted microscope.

Scan several fields in each well to check for even distribution of cells and urine.

Count the numbers, or estimate the range, of WBCs and RBCs per representative field and convert to numbers (or range) per litre.

Enumerate and record SECs.

Enumerate and record casts, if present, and state type.

Record if bacteria, yeasts, \textit{Trichomonas vaginalis}, or significant crystals such as cystine are present.
All procedures for enumeration of cells should be carried out according to local protocols.

**Note 1:** This SMI contains a table of multiplicative factors to correct for variability in microtitre tray well size based on varying volumes of urine dispensed, diameter of well and field of vision diameter (refer to Appendix 1)\(^6\). The number of WBCs counted should be multiplied by the multiplicative factor to take into account all the variables. If the well size, volume of urine dispensed, diameter of well or field of vision diameter are altered, then the multiplicative factor needs to be re-calculated.

**Note 2:** If the microtitre tray is also to be used for culture by multipoint inoculation, it should be stored at 4°C until culture is performed (unless all specimens in the tray are preserved with boric acid when refrigeration is not necessary).

**Note 3:** Microscopy should not be performed on screening specimens sent exclusively for the isolation of *S. Typhi* and *S. Paratyphi* for safety reasons.

### 4.4.2 Alternative methods

See introduction for a discussion on non-culture methods.

Screening by biochemical test strips may be performed in place of microscopy; however, these methods do not detect casts or abnormal cells such as dysmorphic cells.

Automated systems such as those using urine analysers must be validated and used in accordance with manufacturers’ instructions.

### 4.4.3 Supplementary Microscopy for:

- **dysmorphic RBCs**\(^{11,12}\) – Laboratories should consult with local urologists regarding the reporting of dysmorphic RBCs in urine. Fresh specimens (<30min old) are essential

- **Mycobacterium species** – (see [B 40 - Investigation of specimens for Mycobacterium species](#))

- **parasites** – (see [B 31 - Investigation of specimens other than blood for parasites](#))

### 4.5 Culture and investigation

#### 4.5.1 Pre-treatment

**Standard**

N/A

**Supplementary**

*Mycobacterium species* (see [B 40 - Investigation of specimens for Mycobacterium species](#)) and for parasites (see [B 31 - Investigation of specimens other than blood for parasites](#)).

#### 4.5.2 Specimen processing

Choice of culture method is made locally.
Specimens with ‘negative’ microscopy may be given a screening culture only, whereas those with ‘positive’ microscopy may include direct susceptibility testing.

**Calibrated loop/surface streak method**

Mix the urine gently to avoid foaming.

Dip the end of a sterile calibrated loop (eg 1µL, 2µL or 10µL) in the urine to just below the surface and remove vertically, taking care not to carry over any on the shank.

Use this to inoculate CLED or chromogenic agar plate and spread according to the number of specimens (see Q 5 - Inoculation of culture media for bacteriology). A maximum of four samples per 9cm plate is recommended for this method with a 1µL or 2µL loop, or two samples if using a 10µL loop.

If a 1µL loop is used, one colony equals 1000 cfu/mL (ie 1 x 10^6 cfu/L).

**SPAs, other surgically obtained urine, and urine samples with expected significant bacteriuria as low as 10^5 cfu/L (increased inoculum sizes are required)**

Inoculate 100µL (0.1mL) of specimen aseptically to a full CLED or chromogenic agar plate.

Spread inoculum over entire surface of plate with a sterile loop or a spreader. Do not use a sterile swab which will absorb much of the inoculum. To isolate individual colonies, spread inoculum with a sterile loop.

No. of cfu/L = No. of cfu on plate x 10^4.

This semi quantitative method is only sensitive for screening down to 10^5 cfu/L if a 5µL or 10µL loop is used (eg 5 or 10 colonies), or 10^7 cfu/L if a 1µL or 2µL loop is used (eg 10 or 20 colonies). (See table below).

**Guidance on assessing colony counts (with the exception of filter paper strip method; see Introduction for the clinical interpretation results)**

<table>
<thead>
<tr>
<th>Corresponding cfu/L (cfu/mL)</th>
<th>0.3µL</th>
<th>1µL</th>
<th>2µL</th>
<th>5µL</th>
<th>10µL</th>
</tr>
</thead>
<tbody>
<tr>
<td>10^6 cfu/L</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>10^7 cfu/L</td>
<td>3</td>
<td>10</td>
<td>20</td>
<td>50</td>
<td>100</td>
</tr>
<tr>
<td>10^8 cfu/L</td>
<td>30</td>
<td>100</td>
<td>200</td>
<td>500</td>
<td>1000</td>
</tr>
</tbody>
</table>

**Multipoint methods**

**Using 96 pin head microtitre trays**

Prepare microtitre tray and perform microscopy (see Section 4.4).

Label the microtitre tray containing chromogenic or CLED agar medium using the same template as for microscopy (see above Section 4.3.2).

Sterilise the inoculating pins on the multipoint inoculator.

Inoculate the agar microtitre tray with urine (eg 0.3µL, 1µL, 2µL, depending on pin size) from the 60µL aliquots used for microscopy.
Investigation of urine

**Note 1:** The tray must be stored at 4°C until full culture is performed (unless all specimens in the tray are preserved with boric acid).

**Note 2:** To prevent the inoculated agar in the microtitre trays from drying out in the incubator overnight, place the microtitre trays either in a moist box or stack carefully with a lid on the top tray.

**Note 3:** This method is only sensitive for screening down to $10^7$ cfu/L. A larger inoculum may be required in selected patient groups or specimens when greater sensitivity is needed.

**Using agar plates**

Multipoint inoculation of no more than 20 specimens per 9cm plate is recommended.

Prepare inoculum in sterile cupules, arranged according to the configuration of the inoculation head.

Label CLED/chromogenic agar plate to correspond to inoculation configuration.

Sterilise the inoculating pins on the multipoint inoculator.

Dip inoculating pins into inoculum.

Inoculate CLED/chromogenic agar plate.

**Note:** Detection of antimicrobial substances must be undertaken if a multipoint culture method is used with agar plates, rather than microtitre trays, as diffusion of antimicrobial substances from some urine samples may affect neighbouring inocula and give false negative results (see section below: ‘Detection of antimicrobial substances’). Any sample thought to be affected in this way should be retested.

**Filter paper method**

Dip the commercially prepared sterile filter paper strip in the urine up to the mark indicated.

Remove excess urine by touching the edge of the strip against the side of the specimen container. Allow the remaining urine to absorb into the strip before inoculating a CLED or chromogenic agar plate.

Bend the inoculated end of the strip and press flat against the agar for a few seconds.

Several specimens may be inoculated onto one CLED agar plate in this technique, although this is less effective than plating to chromogenic agar, as mixed cultures are easier to detect.

**Note:** This method is only sensitive for screening down to $10^7$ cfu/L. A larger inoculum will be required in selected patient groups or for specimens where lower counts are expected.

**Guidance on assessing colony count using the filter paper strip method**

<table>
<thead>
<tr>
<th>No. cfu counted</th>
<th>Corresponding cfu/L (cfu/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gram negative bacilli</strong></td>
<td><strong>Cocci</strong></td>
</tr>
<tr>
<td>0–5</td>
<td>0–8</td>
</tr>
<tr>
<td>5–25</td>
<td>8–30</td>
</tr>
</tbody>
</table>
Automated methods

Semi-automated systems such as urine analysers must be validated and used in accordance with manufacturers’ instructions.

4.5.3 Other screening methods

Enteric fever screen

Enteric salmonellae may be recovered from urine following pre-enrichment in mannitol selenite, which can be prepared by carefully adding an equal volume of urine to mannitol selenite broth (see section: Safety Considerations).

Detection of antimicrobial substances

This method is performed most easily using multipoint systems, but inoculation of urine is possible with a sterile loop or pipette and disposable tips.

Surface seed plates or microtitre tray containing a defined susceptibility testing agar with a broth culture or spore suspension of Bacillus subtilis (NCTC 10400) diluted to give a semi-confluent growth. B. subtilis is the preferred organism as it is susceptible to a wider range of antimicrobials than either E. coli or S. aureus.

Dry before use.

Inoculate plate or microtitre wells with urine as described earlier, ensuring that the seeded plate is inoculated last to prevent contamination of other media with B. subtilis.
### 4.5.4 Culture media, conditions and organisms

<table>
<thead>
<tr>
<th>Clinical details/conditions</th>
<th>Standard media</th>
<th>Incubation</th>
<th>Cultures read</th>
<th>Target organism(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>UTI</strong></td>
<td>CLED agar or Chromogenic agar</td>
<td>35–37</td>
<td>Air</td>
<td>16–24hr</td>
</tr>
<tr>
<td><strong>Enteric fever screen</strong></td>
<td>Mannitol selenite broth subcultured to: XLD</td>
<td>35–37</td>
<td>Air</td>
<td>16–24hr</td>
</tr>
</tbody>
</table>

For these situations, add the following:

<table>
<thead>
<tr>
<th>Clinical details/conditions</th>
<th>Supplementary media</th>
<th>Incubation</th>
<th>Cultures read</th>
<th>Target organism(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Urine of patients in Intensive Care, Special Care Baby Units, Burns Units and any from a Transplant Unit or if yeast have been seen in microscopy</strong></td>
<td>Sabouraud agar</td>
<td>35–37</td>
<td>Air</td>
<td>40–48hr</td>
</tr>
<tr>
<td><strong>Multipoint culture using agar plates</strong></td>
<td>Susceptibility testing agar seeded with <em>B. subtilis</em> (NCTC 10400)</td>
<td>35–37</td>
<td>Air</td>
<td>16–24hr</td>
</tr>
</tbody>
</table>

### Optional media

<table>
<thead>
<tr>
<th>Clinical details/conditions</th>
<th>Incubation</th>
<th>Cultures read</th>
<th>Target organism(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>If sterile pyuria and no antimicrobials detected</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Fastidious anaerobe agar</strong></td>
<td>35–37</td>
<td>anaerobic</td>
<td>40–48hr</td>
</tr>
<tr>
<td><strong>Chocolate agar</strong></td>
<td>35–37</td>
<td>5-10% CO₂</td>
<td>40–</td>
</tr>
</tbody>
</table>
4.6 Identification

Refer to individual SMI s for organism identification.

4.6.1 Minimum level of identification in the laboratory

**Note:** All work on S. Typhi and S. Paratyphi must be performed in a microbiological safety cabinet under Containment Level 3 conditions.

<table>
<thead>
<tr>
<th>Organism Type</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anaerobes</td>
<td>&quot;anaerobes&quot; level</td>
</tr>
<tr>
<td>β-haemolytic streptococci</td>
<td>Lancefield group level</td>
</tr>
<tr>
<td>Enterobacteriaceae (except Salmonella species)</td>
<td>&quot;coliform&quot; level</td>
</tr>
<tr>
<td>Enterococci</td>
<td>genus level</td>
</tr>
<tr>
<td>Pseudomonads</td>
<td>&quot;pseudomonads&quot; level</td>
</tr>
<tr>
<td>S. saprophyticus</td>
<td>species level</td>
</tr>
<tr>
<td>Other coagulase negative staphylococci</td>
<td>&quot;coagulase negative&quot; level</td>
</tr>
<tr>
<td>S. aureus</td>
<td>species level</td>
</tr>
<tr>
<td>S. Typhi/Paratyphi</td>
<td>species level</td>
</tr>
<tr>
<td>Yeasts</td>
<td>&quot;yeasts&quot; level</td>
</tr>
<tr>
<td>Mycobacterium</td>
<td>B 40 - Investigation of specimens for Mycobacterium species</td>
</tr>
<tr>
<td>Parasites</td>
<td>B 31 - Investigation of specimens other than blood for parasites</td>
</tr>
<tr>
<td>Fungi (in urines from patients species level in Intensive Care, Special Care Baby Units, Burns Units and any from Transplant Units)</td>
<td>species level</td>
</tr>
</tbody>
</table>

Organisms may be further identified if this is clinically or epidemiologically indicated.
## 4.7 Antimicrobial susceptibility testing

Refer to British Society for Antimicrobial Chemotherapy (BSAC), EUCAST and/or CSLI guidelines or manufacturer's validation for proprietary methods.

This SMI recommends selective and restrictive reporting of susceptibilities to antimicrobials. Any deviation must be subject to consultation that should include local antimicrobial stewardship groups.

### 4.7.1 Antimicrobial Susceptibility Testing and Reporting Table

It is recommended that the antimicrobials in bold in the table below are reported. Those antimicrobials not in bold may be reported based on local decisions.

For more information on Detection of Bacteria with Carbapenem-Hydrolysing β-lactamases (Carbapenemases) refer to B 60.

<table>
<thead>
<tr>
<th>Bacteria</th>
<th>Examples of agents to be included within primary test panel (recommended agents to be reported are in bold depending on clinical presentation)</th>
<th>Examples of agents to be considered for supplementary testing (recommended agents to be reported are in bold depending on clinical presentation)</th>
<th>Notes</th>
</tr>
</thead>
</table>
| Enterobacteriaceae | **Ampicillin (or Amoxicillin)**<sup>1</sup>  
Cefpodoxime  
Nitrofurantoin<sup>2</sup>  
Trimethoprim | Amikacin  
Cefalexin  
Cefotaxime (or Ceftriaxone)  
Ceftazidime  
Ciprofloxacin (or Norfloxacin)  
Co-amoxiclav<sup>3</sup>  
Ertapenem  
Fosfomycin  
**Gentamicin**  
Mecillinam  
Meropenem (or Imipenem)  
Piperacillin/Tazobactam  
Temocillin  
Aztreonam | 1. Cefpodoxime resistant organisms should be tested for the presence of ESBLs and screened for reduced susceptibility to carbapenems.  
2. Nitrofurantoin for uncomplicated UTI only  
3. Co-amoxiclav resistant organisms should be tested at a local level for sensitivity to an indicator carbapenem. |
| P. aeruginosa and Acinetobacter spp. | Ceftazidime (for *P. aeruginosa only*)  
Ciprofloxacin  
**Gentamicin**  
Meropenem (or Imipenem)  
Piperacillin/Tazobactam<sup>4</sup> | Amikacin  
Colistin | 4. Tazobactam should not be rested or reported for *Acinetobacter spp.* |
### Investigation of urine

<table>
<thead>
<tr>
<th>Organism</th>
<th>Susceptible Antibiotics</th>
<th>Resistance Antibiotics</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>S. saprophyticus</em></td>
<td>Cefoxitin (or Oxacillin)</td>
<td>Nitrofurantoin (uncomplicated UTI only)</td>
<td>5. Report as Flucloxacillin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trimethoprim</td>
<td></td>
</tr>
<tr>
<td><em>S. aureus</em> and other coagulase negative Staphylococci</td>
<td>Cefoxitin (or Oxacillin)</td>
<td>Gentamicin</td>
<td>5. Report as Flucloxacillin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tetracycline</td>
<td>6. Supress report in children and pregnant women</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Triamthoprim</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nitrofurantoin</td>
<td></td>
</tr>
<tr>
<td>Group B Beta-Haemolytic Streptococci</td>
<td>Nitrofurantoin</td>
<td>Clindamycin</td>
<td>2. Nitrofurantoin for uncomplicated UTI only may be useful in interpretation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Penicillin</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trimethoprim</td>
<td></td>
</tr>
<tr>
<td>Enterococcus spp.</td>
<td>Ampicillin (or Amoxicillin)</td>
<td>Teicoplanin</td>
<td>2. Nitrofurantoin for uncomplicated UTI only</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nitrofurantoin</td>
<td></td>
</tr>
</tbody>
</table>

### 4.8 Referral for outbreak investigations

N/A

### 4.9 Referral to reference laboratories

For information on the tests offered, turnaround times, transport procedure and the other requirements of the reference laboratory click here for user manuals and request forms.

Organisms with unusual or unexpected resistance, or associated with a laboratory or clinical problem, or anomaly that requires elucidation should be sent to the appropriate reference laboratory.

Contact appropriate devolved national reference laboratory for information on the tests available, turnaround times, transport procedure and any other requirements for sample submission:

**England and Wales**


**Scotland**

5 Reporting procedure

5.1 Microscopy

5.1.1 Microscopy
Report on the actual numbers, or range of WBCs and RBCs per litre or per mL according to local protocol.

Report on the presence of bacteria, epithelial cells, casts, yeasts and *T. vaginalis*.

Report on supplementary microscopy for dysmorphic RBCs, (see B 40 - Investigation of specimens for *Mycobacterium* species) and parasites (see B 31 - Investigation of specimens other than blood for parasites).

5.1.2 Chemical and semi automated screening methods
Report the results obtained together with a quantitative interpretation if applicable.

The following comments may be added:

“Culture not indicated – bacterial count below significant threshold”.

“If symptoms persist or recur please submit a further sample indicating culture required”.

5.1.3 Microscopy or chemical screening reporting time
All results should be issued to the requesting clinician as soon as they become available, unless specific alternative arrangements have been made with the requestors.

Urgent results should be telephoned or transmitted electronically in accordance with local policies.

5.1.4 Urine for antigen testing

**Positives**

*Legionella pneumophila* urine antigen positive

**Comment** – Provisional positive for *Legionella pneumophila* serogroup 1 antigen in urine. Please send a respiratory sample for Legionella culture. Specimen has been referred to the Reference laboratory for confirmatory testing.

**Negatives**

*Legionella pneumophila* serogroup 1 urine antigen not detected

5.2 Culture

Report bacterial growth in either metric or SI units, according to local protocol (see section: Technical Information/Limitations at end of Introduction).

Including comments where appropriate (refer to Appendix 3) or

Report no significant growth or
Report absence of growth.

Report presence of antimicrobial substances, if detected.

Report results of supplementary investigations.

5.2.1 Culture reporting time

Interim or preliminary results should be issued on detection of potentially clinically significant isolates as soon as growth is detected, unless specific alternative arrangements have been made with the requestors.

Urgent results should be telephoned or transmitted electronically in accordance with local policies.

Final written or computer generated reports should follow preliminary and verbal reports as soon as possible.

Supplementary investigations: Mycobacterium species (see B 40 - Investigation of specimens for Mycobacterium species) and parasites (see B 31 - Investigation of specimens other than blood for parasites).

5.3 Antimicrobial susceptibility testing

Report susceptibilities as clinically indicated. Prudent use of antimicrobials according to local and national protocols is recommended.

Refer to table 4.7.1. The table includes guidance on some of the agents that should be tested on the bacterial isolates listed. The table also includes additional agents that can be considered for inclusion in test panels in specific clinical scenarios.

Any deviation from the guidance should be subject to local consultation and risk assessment.

Generally, all non-intrinsic resistant results should be reported as this is good practice and informs the user.
6 Notification to PHE\textsuperscript{128,129}, or equivalent in the devolved administrations\textsuperscript{130-133}

The Health Protection (Notification) regulations 2010 require diagnostic laboratories to notify Public Health England (PHE) when they identify the causative agents that are listed in Schedule 2 of the Regulations. Notifications must be provided in writing, on paper or electronically, within seven days. Urgent cases should be notified orally and as soon as possible, recommended within 24 hours. These should be followed up by written notification within seven days.

For the purposes of the Notification Regulations, the recipient of laboratory notifications is the local PHE Health Protection Team. If a case has already been notified by a registered medical practitioner, the diagnostic laboratory is still required to notify the case if they identify any evidence of an infection caused by a notifiable causative agent.

Notification under the Health Protection (Notification) Regulations 2010 does not replace voluntary reporting to PHE. The vast majority of NHS laboratories voluntarily report a wide range of laboratory diagnoses of causative agents to PHE and many PHE Health protection Teams have agreements with local laboratories for urgent reporting of some infections. This should continue.

Note: The Health Protection Legislation Guidance (2010) includes reporting of Human Immunodeficiency Virus (HIV) & Sexually Transmitted Infections (STIs), Healthcare Associated Infections (HCAIs) and Creutzfeldt–Jakob disease (CJD) under ‘Notification Duties of Registered Medical Practitioners’: it is not noted under ‘Notification Duties of Diagnostic Laboratories’.

https://www.gov.uk/government/organisations/public-health-england/about/our-governance#health-protection-regulations-2010

Other arrangements exist in Scotland\textsuperscript{130,131}, Wales\textsuperscript{132} and Northern Ireland\textsuperscript{133}.
### Appendix 1: Multiplicative factors based on varying volumes of urine dispensed, diameter of well & field of vision (Fov) diameter

<table>
<thead>
<tr>
<th>Volume of urine dispensed (μL)</th>
<th>80</th>
<th>80</th>
<th>80</th>
<th>80</th>
<th>80</th>
<th>80</th>
<th>80</th>
<th>80</th>
<th>80</th>
<th>80</th>
<th>80</th>
<th>80</th>
<th>80</th>
<th>80</th>
<th>80</th>
<th>80</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diameter of well (mm)</td>
<td>8.00</td>
<td>8.00</td>
<td>8.00</td>
<td>8.00</td>
<td>8.00</td>
<td>8.00</td>
<td>7.00</td>
<td>7.00</td>
<td>7.00</td>
<td>7.00</td>
<td>6.00</td>
<td>6.00</td>
<td>6.00</td>
<td>6.00</td>
<td>6.00</td>
<td>6.00</td>
</tr>
<tr>
<td>FOV diameter (mm)</td>
<td>1.00</td>
<td>0.90</td>
<td>0.80</td>
<td>0.70</td>
<td>0.60</td>
<td>0.50</td>
<td>1.00</td>
<td>0.90</td>
<td>0.80</td>
<td>0.70</td>
<td>0.60</td>
<td>0.50</td>
<td>1.00</td>
<td>0.90</td>
<td>0.80</td>
<td>0.70</td>
</tr>
<tr>
<td>Multiplicative Factor</td>
<td>0.80</td>
<td>1.00</td>
<td>1.30</td>
<td>1.60</td>
<td>2.20</td>
<td>3.20</td>
<td>0.60</td>
<td>0.80</td>
<td>1.00</td>
<td>1.30</td>
<td>1.70</td>
<td>2.50</td>
<td>0.50</td>
<td>0.60</td>
<td>0.70</td>
<td>0.90</td>
</tr>
<tr>
<td>Multiplicative Factor (rounded)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0.005</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Volume of urine dispensed (μL)</th>
<th>70</th>
<th>70</th>
<th>70</th>
<th>70</th>
<th>70</th>
<th>70</th>
<th>70</th>
<th>70</th>
<th>70</th>
<th>70</th>
<th>70</th>
<th>70</th>
<th>70</th>
<th>70</th>
<th>70</th>
<th>70</th>
<th>70</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diameter of well (mm)</td>
<td>8.00</td>
<td>8.00</td>
<td>8.00</td>
<td>8.00</td>
<td>8.00</td>
<td>8.00</td>
<td>7.00</td>
<td>7.00</td>
<td>7.00</td>
<td>7.00</td>
<td>6.00</td>
<td>6.00</td>
<td>6.00</td>
<td>6.00</td>
<td>6.00</td>
<td>6.00</td>
<td>6.00</td>
</tr>
<tr>
<td>FOV diameter (mm)</td>
<td>1.00</td>
<td>0.90</td>
<td>0.80</td>
<td>0.70</td>
<td>0.60</td>
<td>0.50</td>
<td>1.00</td>
<td>0.90</td>
<td>0.80</td>
<td>0.70</td>
<td>0.60</td>
<td>0.50</td>
<td>1.00</td>
<td>0.90</td>
<td>0.80</td>
<td>0.70</td>
<td>0.50</td>
</tr>
<tr>
<td>Multiplicative Factor</td>
<td>0.90</td>
<td>1.10</td>
<td>1.40</td>
<td>1.90</td>
<td>2.50</td>
<td>3.70</td>
<td>0.70</td>
<td>0.90</td>
<td>1.10</td>
<td>1.40</td>
<td>1.90</td>
<td>2.80</td>
<td>0.50</td>
<td>0.60</td>
<td>0.80</td>
<td>1.00</td>
<td>1.40</td>
</tr>
<tr>
<td>Multiplicative Factor (rounded)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Volume of urine dispensed (μL)</th>
<th>60</th>
<th>60</th>
<th>60</th>
<th>60</th>
<th>60</th>
<th>60</th>
<th>60</th>
<th>60</th>
<th>60</th>
<th>60</th>
<th>60</th>
<th>60</th>
<th>60</th>
<th>60</th>
<th>60</th>
<th>60</th>
<th>60</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diameter of well (mm)</td>
<td>8.00</td>
<td>8.00</td>
<td>8.00</td>
<td>8.00</td>
<td>8.00</td>
<td>8.00</td>
<td>7.00</td>
<td>7.00</td>
<td>7.00</td>
<td>7.00</td>
<td>6.00</td>
<td>6.00</td>
<td>6.00</td>
<td>6.00</td>
<td>6.00</td>
<td>6.00</td>
<td>6.00</td>
</tr>
<tr>
<td>FOV diameter (mm)</td>
<td>1.00</td>
<td>0.90</td>
<td>0.80</td>
<td>0.70</td>
<td>0.60</td>
<td>0.50</td>
<td>1.00</td>
<td>0.90</td>
<td>0.80</td>
<td>0.70</td>
<td>0.60</td>
<td>0.50</td>
<td>1.00</td>
<td>0.90</td>
<td>0.80</td>
<td>0.70</td>
<td>0.50</td>
</tr>
<tr>
<td>Multiplicative Factor</td>
<td>1.10</td>
<td>1.30</td>
<td>1.70</td>
<td>2.20</td>
<td>3.00</td>
<td>4.30</td>
<td>0.80</td>
<td>1.00</td>
<td>1.30</td>
<td>1.70</td>
<td>2.30</td>
<td>3.30</td>
<td>0.60</td>
<td>0.70</td>
<td>0.90</td>
<td>1.20</td>
<td>1.70</td>
</tr>
<tr>
<td>Multiplicative Factor (rounded)</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>
Appendix 2: Multiplicative factor equation

Multiplicative Factor for Appendix 1

\[
\text{Multiplicative factor} = \frac{1}{\text{Volume observed (}V_o\text{)}},
\]

\[
V_o = \pi (\text{FOVr})^2 \times \text{fd}
\]

\[
\text{Fluid depth (}fd\text{)} = \frac{\text{Volume dispensed}}{\pi (\text{Radius of the well})^2}
\]

Where:

\(\pi\) – Known as Pi whose constant value is known as 3.14

FOVr - The radius of the Field of Vision (in , calculated by dividing the diameter of the FOV which is calculated as FOV number (marked on eyepiece) divided by the objective magnification or by direct measurement with a micrometre.)
### Appendix 3: Guidance for the interpretation of urine culture

**Note:** This table is intended for guidance only - supplementation with local reporting policies may be necessary.

<table>
<thead>
<tr>
<th>Growth cfu/L</th>
<th>No. isolates</th>
<th>Specimen type</th>
<th>Clinical details/microscopy influencing report*</th>
<th>Laboratory interpretation</th>
<th>Susceptibility testing recommended</th>
<th>Comments to consider</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥10⁸</td>
<td>1</td>
<td>Any</td>
<td>None</td>
<td>Probable UTI</td>
<td>Yes</td>
<td>If old specimen or no pyuria consider repeat to confirm Consider SPA or CCU if bag specimen</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Each org ≥10⁶ or ≥10⁵ and ≥10⁷</td>
<td>MSU, CCU, SCU, BAG</td>
<td>WBC present Symptomatic</td>
<td>Possible UTI – colonisation, faulty collection or transport</td>
<td>Yes</td>
<td>Consider repeat to confirm</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CSU, (IL)</td>
<td>Indwelling catheter Neurogenic bladder</td>
<td>Probable colonisation</td>
<td>No – Consider keeping plates ≤ 5d in case patient becomes septic Consider discuss if patient systemically unwell and therapy required</td>
<td></td>
</tr>
<tr>
<td>≥3</td>
<td>Mixed growth - none predominant</td>
<td>Any</td>
<td>None</td>
<td>Faulty collection or transport</td>
<td>No</td>
<td>Heavy mixed growth – probable contamination. Consider repeat if symptomatic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10⁷ – 10⁸</td>
<td>1</td>
<td>Any</td>
<td>WBC present Symptomatic</td>
<td>Possible UTI – patient evaluation necessary</td>
<td>Yes</td>
<td>Consider repeat to confirm</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>1 predominant at ≥10⁷</td>
<td>Any</td>
<td>WBC present Symptomatic Children</td>
<td>Probable UTI with predominant species 2nd isolate probable contamination</td>
<td>Yes, predominant organism but suppress results</td>
<td>Consider repeat or SPA/CCU Sensitivities are available if required</td>
</tr>
<tr>
<td></td>
<td>1 at &lt; 10⁷ or - 10⁷ but not predominant</td>
<td>None</td>
<td>Probable contamination</td>
<td></td>
<td>No</td>
<td>Mixed growth – probable contamination</td>
</tr>
<tr>
<td>≥3</td>
<td>1 organism predominant at ≥10⁷</td>
<td>Any</td>
<td>WBC present Symptomatic</td>
<td>Possible UTI with predominant species. Others probable contamination</td>
<td>No – keep plates ≤ 5d if catheter specimen in case patient becomes septic Mixed growth – consider repeat if symptomatic</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CSU</td>
<td>Indwelling catheter Neurogenic bladder</td>
<td>Colonisation</td>
<td>No – keep plates ≤ 5d in case patient becomes septic</td>
<td>Please discuss if therapy indicated</td>
</tr>
</tbody>
</table>
Appendix 3 (continued): Guidance for the interpretation of urine culture

**Note:** This table is intended for guidance only – supplementation with local reporting policies may be necessary.

<table>
<thead>
<tr>
<th>Growth cfu/L</th>
<th>No. isolates</th>
<th>Specimen type</th>
<th>Clinical details/microscopy influencing report</th>
<th>Laboratory interpretation</th>
<th>Susceptibility testing recommended</th>
<th>Comments to consider</th>
</tr>
</thead>
<tbody>
<tr>
<td>$10^6$ – $10^7$</td>
<td>1</td>
<td>MSU, CCU, CSU, IL</td>
<td>Symptomatic female Prostatitis WBC present</td>
<td>Possible UTI – clinical evaluation necessary</td>
<td>Yes</td>
<td>Consider repeat to confirm</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>Any</td>
<td>Each org $\geq 10^6$ - including possible pathogen, eg E. coli or S. saprophyticus</td>
<td>Possible UTI – clinical evaluation necessary</td>
<td>Yes</td>
<td>Consider repeat to confirm</td>
</tr>
<tr>
<td>$10^5$ – $10^6$</td>
<td>1</td>
<td>SPA, CYS, (SCU)</td>
<td>None</td>
<td>Probable UTI</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td></td>
<td>Each $\geq 10^6$ WBC present</td>
<td>Probable UTI – patient evaluation necessary</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$\geq 3$</td>
<td>WBC present</td>
<td>1 organism predominant at $\geq 10^6$</td>
<td>Probable UTI – patient evaluation necessary</td>
<td>Yes, predominant organism</td>
<td>Mixed growth: Consider repeat to confirm</td>
</tr>
<tr>
<td>No growth</td>
<td></td>
<td>Any</td>
<td>(&lt; 10^6) if 1 μL loop used (&lt; 10^5) if 10 μL loop used</td>
<td>None or asymptomatic</td>
<td>No UTI</td>
<td></td>
</tr>
</tbody>
</table>

**MSU** – Midstream specimen; **CCU** – clean catch; **SPA** – Suprapubic aspirate; **IL** – Ileal conduit; **CSU** – Catheter; **SCU** – Single, intermittent catheter (“in and out”); **CYS** – Cystoscopy

* - see Introduction for interpretation of culture results
Modified GRADE table used by UK SMIs when assessing references

Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) is a systematic approach to assessing references. A modified GRADE method is used in UK SMIs for appraising references for inclusion. Each reference is assessed and allocated a grade for strength of recommendation (A-D) and quality of the underlying evidence (I-VI). A summary table which defines the grade is listed below and should be used in conjunction with the reference list.

<table>
<thead>
<tr>
<th>Strength of recommendation</th>
<th>Quality of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>A  Strongly recommended</td>
<td>I  Evidence from randomised controlled trials, meta-analysis and systematic reviews</td>
</tr>
<tr>
<td>B  Recommended but other alternatives may be acceptable</td>
<td>II  Evidence from non-randomised studies</td>
</tr>
<tr>
<td>C  Weakly recommended: seek alternatives</td>
<td>III  Non-analytical studies, eg case reports, reviews, case series</td>
</tr>
<tr>
<td>D  Never recommended</td>
<td>IV  Expert opinion and wide acceptance as good practice but with no study evidence</td>
</tr>
<tr>
<td></td>
<td>V  Required by legislation, code of practice or national standard</td>
</tr>
<tr>
<td></td>
<td>VI Letter or other</td>
</tr>
</tbody>
</table>


Bacteriology | B 41 | Issue no: 8.7 | Issue date: 11.01.19 | Page: 47 of 51


96. European Parliament. UK Standards for Microbiology Investigations (SMIs) use the term "CE marked leak proof container" to describe containers bearing the CE marking used for the collection and transport of clinical specimens. The requirements for specimen containers are given in the EU in vitro Diagnostic Medical Devices Directive (98/79/EC Annex 1 B 2.1) which states: "The design must allow easy handling and, where necessary, reduce as far as possible contamination of, and leakage from, the device during use and, in the case of specimen receptacles, the risk of contamination of the specimen. The manufacturing processes must be appropriate for these purposes". 1998.


107. van der Zwet WC, Hessels J, Canbolat F, Deckers MM. Evaluation of the Sysmex UF-1000i(R) urine flow cytometer in the diagnostic work-up of suspected urinary tract infection in a Dutch general hospital. Clinical chemistry and laboratory medicine 2010;48:1765-71. B, II


